SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001849682-22-000004
Filing Date
2022-06-02
Accepted
2022-06-02 17:38:41
Documents
3
Period of Report
2022-05-31

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_165420589977053.html 3  
1 FORM 3 wf-form3_165420589977053.xml 3 3424
2 EXHIBIT 24 - DHINGRA exhibit24-dhingra.htm EX-24 2584
3 EXHIBIT 24 - DHINGRA exhibit24-dhingra001.jpg GRAPHIC 144723
  Complete submission text file 0001849682-22-000004.txt   207027
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 617-514-7149
Summit Therapeutics Inc. (Issuer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CAREDX, INC. 1 TOWER PLACE, 9TH FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Dhingra Ankur (Reporting) CIK: 0001849682 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36866 | Film No.: 22992188